BR112022011797A2 - Anticorpos contra receptor alfa de interleucina-4 canino - Google Patents

Anticorpos contra receptor alfa de interleucina-4 canino

Info

Publication number
BR112022011797A2
BR112022011797A2 BR112022011797A BR112022011797A BR112022011797A2 BR 112022011797 A2 BR112022011797 A2 BR 112022011797A2 BR 112022011797 A BR112022011797 A BR 112022011797A BR 112022011797 A BR112022011797 A BR 112022011797A BR 112022011797 A2 BR112022011797 A2 BR 112022011797A2
Authority
BR
Brazil
Prior art keywords
receptor alpha
canine
antibodies against
antibodies
against canine
Prior art date
Application number
BR112022011797A
Other languages
English (en)
Inventor
Morsey Mohamad
Zhang Yuanzheng
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112022011797A2 publication Critical patent/BR112022011797A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ANTICORPOS CONTRA RECEPTOR ALFA DE INTERLEUCINA-4 CANINO. A presente invenção fornece anticorpos para o receptor alfa de IL-4 canino que têm uma alta afinidade de ligação para o receptor alfa de IL-4 canino, e que podem bloquear a ligação da IL 4 canina e/ou IL 13 canina ao receptor alfa de IL-4 canino. A presente invenção está adicionalmente relacionada a epítopos do receptor alfa de IL-4 que se ligam aos anticorpos para o receptor alfa de IL 4 canino. A presente invenção fornece adicionalmente o uso dos anticorpos para o tratamento de dermatite atópica em cães.
BR112022011797A 2019-12-20 2020-12-18 Anticorpos contra receptor alfa de interleucina-4 canino BR112022011797A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962951778P 2019-12-20 2019-12-20
US201962951793P 2019-12-20 2019-12-20
US202063015209P 2020-04-24 2020-04-24
US202063015220P 2020-04-24 2020-04-24
PCT/EP2020/086921 WO2021123091A1 (en) 2019-12-20 2020-12-18 Canine interleukin-4 receptor alpha antibodies

Publications (1)

Publication Number Publication Date
BR112022011797A2 true BR112022011797A2 (pt) 2022-08-30

Family

ID=74183109

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022011797A BR112022011797A2 (pt) 2019-12-20 2020-12-18 Anticorpos contra receptor alfa de interleucina-4 canino
BR112022012203A BR112022012203A2 (pt) 2019-12-20 2020-12-18 Anticorpos para receptor alfa da interleucina-4 canino

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112022012203A BR112022012203A2 (pt) 2019-12-20 2020-12-18 Anticorpos para receptor alfa da interleucina-4 canino

Country Status (9)

Country Link
US (2) US20230053131A1 (pt)
EP (2) EP4077390A1 (pt)
JP (2) JP2023506924A (pt)
CN (2) CN114867526A (pt)
AU (2) AU2020409583A1 (pt)
BR (2) BR112022011797A2 (pt)
CA (2) CA3160589A1 (pt)
MX (2) MX2022007677A (pt)
WO (2) WO2021123089A1 (pt)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
EP2264166B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7208579B2 (en) 2003-05-30 2007-04-24 The Regents Of The University Of California IL4 receptor antagonists for horse, dog and cat
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
CA3154540A1 (en) 2013-12-20 2015-06-25 Intervet International B.V. CANINIZED ANTIBODIES
AU2016239858B2 (en) 2015-04-02 2021-07-01 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
WO2017102920A1 (en) * 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use

Also Published As

Publication number Publication date
BR112022012203A2 (pt) 2022-09-13
CA3162031A1 (en) 2021-06-24
AU2020407853A1 (en) 2022-06-09
JP2023506923A (ja) 2023-02-20
MX2022007677A (es) 2022-07-19
WO2021123091A1 (en) 2021-06-24
MX2022007672A (es) 2022-07-19
EP4077390A1 (en) 2022-10-26
US20230044037A1 (en) 2023-02-09
AU2020409583A1 (en) 2022-06-09
JP2023506924A (ja) 2023-02-20
EP4076653A1 (en) 2022-10-26
WO2021123089A1 (en) 2021-06-24
US20230053131A1 (en) 2023-02-16
CA3160589A1 (en) 2021-06-24
CN114929746A (zh) 2022-08-19
CN114867526A (zh) 2022-08-05

Similar Documents

Publication Publication Date Title
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
EP3954710A3 (en) Antibodies to canine interleukin-4 receptor alpha
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
CO2019003809A2 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR112015022123A8 (pt) Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit
BR112019002168A2 (pt) anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudina
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
MX2020009568A (es) Anticuerpos que se unen a cd39 y sus usos.
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
BR112018000696A2 (pt) ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
BR112018006360A2 (pt) anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
BR112022011629A2 (pt) Anticorpos biespecíficos caninizados para tratar dermatite atópica
BR112016014293A2 (pt) região de fragmento cristalizável canino, anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, e, método para aumentar a atividade de uma célula imune
IN2014DN08011A (pt)
BR112016007348A2 (pt) membro de ligação específica que se liga ao receptor do fator de crescimento epidérmico humano 2 (her2) para uso em um método de tratamento do câncer em um paciente, método de tratamento de câncer em um paciente, método de identificação de um câncer em um paciente, método para prognosticar a resposta de um câncer
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
BR112012016992A2 (pt) "funcionalidade que se liga a uma interface de contato assimétrico de um recpetor de tirosina quinase (rtk), hibridoma, composição farmacêutica, uso de uma quantidade efixaz da funcionalidade, método para identificar uma funcionalidade que se liga a uma interface de contato assimétrico de um receptor de tirosina quinase (rtk), e, molécula pequena".
BR112012010266A2 (pt) anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para preparar um anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, e para tratar um distúrbio inflamatório, e, uso de um anticorpo ou fragmento de ligação a fkn do mesmo
BR112017001782A2 (pt) fragmentos de anticorpo radiomarcados para uso na prevenção e/ou tratamento de câncer
BR112019000306A2 (pt) chapa de aço e chapa de aço galvanizada
BR112021023540A2 (pt) Agentes de afinidade
AU2021269176A8 (en) Single domain antibodies binding to SARS-CoV-2 spike protein